e-learning
resources
Vienna 2003
Sunday 28.09.2003
Lung cancer management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Gefitinib (‘Iressa’, ZD1839) improves disease-related symptoms in NSCLC
Source:
Annual Congress 2003 - Lung cancer management
Session:
Lung cancer management
Session type:
Poster Discussion
Number:
311
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Gefitinib (‘Iressa’, ZD1839) improves disease-related symptoms in NSCLC. Eur Respir J 2003; 22: Suppl. 45, 311
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
A 12-year-old male child with fever, productive cough and sudden onset paralysis
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
The results of gefitinib (Iressa) treatment in 89 patients with advanced non-small cell lung cancer (NSCLC) on expanded access programme (EAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 753s
Year: 2006
Predictors of response to ZD1839 (IressaÔ) in refractory non-small cell lung cancer
Source: Annual Congress 2004 - Management of lung cancer and innovative therapies
Year: 2004
The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007
Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006
Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily at 1250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006
The importance of symptom improvement with gefitinib in NSCLC
Source: Annual Congress 2004 - Gefitinib (Iressa) in NSCLC: A real alternative to chemotherapy
Year: 2004
EGFR tyrosine kinase inhibitors
versus
chemotherapy in
EGFR
wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017
Year: 2017
Erlotinib as salvage treatment after failure to gefitinib in non-small cell lung cancer
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic.
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
Source: Eur Respir J 2015; 46: 219-229
Year: 2015
Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008
Combination of erlotinib and bevacizumab in non small cell lung cancer patients
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Docetaxel (DOC) and gemcitabine (GEM) consist a safe and effective combination in the management of non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003
Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002
Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2011; 39: 172-179
Year: 2012
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2012; 39: 172-179
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept